On May 21, RemeGen rose 3.55% in regular trading, trading at HK$88.6/share, with trading volume of approximately HK$112 million.

On the news front, the broader biotechnology sector staged a collective rebound, with AKESO surging 7.3%, INNOVENT BIO up 3.4%, SKB BIO up 4.03%, and BEIGENE gaining 3.2%, creating a strong sector linkage effect that lifted sentiment across the board.

From a fundamental perspective, RemeGen's chairman recently stated that telitacicept, having received FDA orphan drug designation, is largely insulated from U.S. drug price reduction policies, and overseas clinical communications with the FDA are progressing smoothly. The company reported Q1 revenue of RMB 656 million, up 24.76% year-over-year, with net profit attributable to shareholders of RMB 328 million, successfully turning losses into profits. Nine institutions have issued buy ratings with an average target price of RMB 150.8, as multiple positive catalysts converge to support price recovery.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)